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Significance of this study
What is already known on this subject?
 ► The myeloid differentiation factor Schlafen4 
(Slfn4) marks a subset of myeloid- derived 
suppressor cells (MDSCs) in the stomach 
during Helicobacter- induced spasmolytic 
polypeptide- expressing metaplasia, which is an 
early committed step appearing prior to gastric 
cancer.
What are the new findings?
 ► MIR130b produced by SLFN4+ MDSCs plays an 
essential role in MDSC function and the levels 
in the blood correlate with metaplastic changes 
in the stomach.
How might it impact on clinical practice in the 
foreseeable future?
 ► MIR130b has potential as an early non- invasive 
diagnostic and therapeutic biomarker for 
metaplastic changes in the stomach that could 
progress to gastric cancer.
AbSTrACT
The myeloid differentiation factor schlafen4 (slfn4) marks 
a subset of myeloid- derived suppressor cells (MDscs) in 
the stomach during Helicobacter- induced spasmolytic 
polypeptide- expressing metaplasia (sPeM).
Objective To identify the gene products expressed 
by slfn4+- MDscs and to determine how they promote 
sPeM.
Design We performed transcriptome analyses for both 
coding genes (mrna by rna- seq) and non- coding 
genes (micrornas using nanostring ncounter) using 
flow- sorted slFn4+ and slFn4– cells from Helicobacter- 
infected mice exhibiting metaplasia at 6 months 
postinfection. Thioglycollate- elicited myeloid cells from 
the peritoneum were cultured and treated with iFnα 
to induce the T cell suppressor phenotype, expression 
of Mir130b and slFn4. Mir130b expression in human 
gastric tissue including gastric cancer and patient sera 
was determined by qPcr and in situ hybridisation. 
Knockdown of Mir130b in vivo in Helicobacter- 
infected mice was performed using invivofectamine. 
Organoids from primary gastric cancers were used to 
generate xenografts. chiP assay and Western blots 
were performed to demonstrate nFκb p65 activation by 
Mir130b.
results Microrna analysis identified an increase in 
Mir130b in gastric slFn4+ cells. Moreover, Mir130b 
colocalised with slFn12l, a human homologue of 
slFn4, in gastric cancers. Mir130b was required for the 
T- cell suppressor phenotype exhibited by the slFn4+ cells 
and promoted Helicobacter- induced metaplasia. Treating 
gastric organoids with the Mir130b mimic induced 
epithelial cell proliferation and promoted xenograft 
tumour growth.
Conclusion Taken together, Mir130b plays an 
essential role in MDsc function and supports metaplastic 
transformation.
InTrODuCTIOn
Metaplastic changes in the stomach typically follow 
chronic inflammation initiated by Helicobacter and 
precede neoplastic transformation. We previously 
reported that a subset of Hedgehog(Hh)- Gli1- 
dependent immune cells are recruited to the gastric 
epithelium during Helicobacter infection in mice 
and polarise into myeloid- derived suppressor cells 
(MDSCs),1 an event that coincides with parietal cell 
atrophy and spasmolytic polypeptide- expressing 
metaplasia (SPEM).2 MDSCs are a heterogeneous 
population of immature myeloid cells,3 and a subset 
increase their expression of Schlafen4 (SLFN4). 
SLFNs are a family of molecules strongly induced 
by type 1 interferons (IFNα), which has been impli-
cated in lymphoid and myeloid cell development and 
differentiation.4 In particular, SLFN4 is a myeloid 
cell differentiation factor that regulates myelopoi-
esis.5 We previously demonstrated that SLFN4+ 
cells originate in the bone marrow, migrate to the 
stomach during Helicobacter infection and require 
Hh signalling. By sorting fluorescently tagged 
SLFN4+ cells from the stomachs of Helicobacter- 
infected mice, we showed that recruited SLFN4+ 
cells acquire their T cell suppressor phenotype 4–6 
months following infection.6 Similar to murine 
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SLFN4, protein expression of the human homologue SLFN12L 
increases in patients with Helicobacter pylori infection with 
intestinal metaplasia and also marks a population of MDSCs.6
Ostensibly, the immune suppressive function of MDSCs 
emerges to dampen the active inflammatory process on presumed 
resolution of the Helicobacter infection. However, inherent in 
resolving the mucosal damage, secretion of pro- proliferative 
signals from the myeloid cells creates a permissive environment 
for hyperplasia, metaplasia and eventually tumour formation.7 
To define the underlying mechanism that drives the emergence 
of this myeloid cell subpopulation and investigate its role in 
tumour progression, we performed transcriptome analyses for 
both coding genes (mRNA by RNA- Seq) and non- coding genes 
(microRNAs using NanoString nCounter) using flow- sorted 
SLFN4+ and SLFN4– myeloid cells from the stomachs, bone 
marrow and spleens of Helicobacter- infected mice. MicroRNAs 
(miRNAs) are endogenous small, non- coding RNAs that nega-
tively regulate target gene expression. Secreted miRNAs are 
recognised as mediators of intercellular communication.8 Given 
their stability in the blood, they can serve as stable circulating 
biomarkers of disease.9 Here, we show that SLFN4+- MDSCs 
isolated from the metaplastic mouse stomach express MiR130b. 
Moreover, we identified elevated levels of MIR130b in the 
serum of both Helicobacter- infected mice and human patients 
that correlated with the respective metaplastic changes in the 
stomach.
reSulTS
rnA profiling of SlFn4+ and SlFn4– cells
We flow- sorted Slfn4- tdTomato+ (SLFN4+) and Slfn4- tdTomato- 
(SLFN4–) myeloid cells (CD11b+) from the stomachs, bone 
marrow and spleens of Slfn4- CreERT2:Rosa- LSL- tdTomato mice 
infected with Helicobacter felis (H. felis) for 6 months. The cells 
were profiled using two high throughput genome- wide analyses 
(RNAseq and miRNA Nanostring nCounter).
RNAseq identified over 5000 differentially expressed genes 
(fold change >2) from stomach SLFN4+ (ST4+) compared 
with bone marrow SLFN4+ (BM4+) and splenic SLFN4+ cells 
(SP4+) as well as stomach SLFN4– cells (ST4–) (online supple-
mentary figure S1A). The hierarchical clustering heat map 
displayed distinct transcriptome profiles for ST4+ cells (online 
supplementary figure S1B), demonstrating that a distinct gene 
expression signature was acquired in the stomach. Many of the 
highly induced transcripts identified in the ST4+ cells were 
consistent with MDSC polarisation (online supplementary figure 
S1C). A subset of these genes was validated by qPCR (online 
supplementary figure S1D- L). Of note, MDSCs express high 
levels of inducible nitric oxide synthase (NOS2) and arginase 
I (ARG1), which consume L- arginine in the microenvironment 
to produce nitric oxide and reactive oxygen species.10 Reduced 
L- arginine blocks TCR- ζ chain synthesis and T cell prolifera-
tion. Transcripts encoding these two major effector enzymes, 
especially NOS2, were highly expressed in the gastric ST4+ 
myeloid cells, but were significantly less in the bone marrow 
and spleen, consistent with our prior findings that acquisition of 
MDSC function occurs in the stomach.6
Using the Nanostring nCounter profiling, we found that 
differences in microRNA expression in ST4+ cells differed from 
the BM4+ and SP4+ gene signatures (figure 1A). Thirty- five 
differentially expressed miRNAs (>2- fold) were identified by 
comparing ST4+ cells to ST4– cells. Moreover, 36 transcripts 
were differentially expressed by comparing ST4+ to the BM4+ 
and SP4+ cells (figure 1B). Of the 13 miRNAs that overlapped 
between the two groups, 12 miRNAs were significantly 
suppressed while only Mir130b was induced (figure 1B).
Mir130b correlates with mouse SlFn4 and human SlFn12l 
expression
To determine whether MiR130b expressed in the gastric 
SLFN4+- MDSCs correlated with its expression in serum, 
MiR130b expression was measured in gastric extracts and serum 
over 6 months following H. felis infection. MiR130b increased 
in both the sera and gastric tissues from infected mice (online 
supplementary figure S2), which coincided with Slfn4 mRNA 
induction and the appearance of Helicobacter- induced SPEM 
as previously reported.6 Thioglycollate (TG)- elicited peritoneal 
cells were treated ex vivo with IFNα to induce myeloid cell 
polarisation6 and peak expression of both Slfn4 and MiR130b 
within 24 hours (figure 2A). MiR130b in situ hybridisation (ISH) 
was performed showing MiR130b localisation to the SLFN4+ 
myeloid cells (figure 2B). To determine if these SLFN4+ MDSCs 
released MiR130b, SLFN4+ and SLFN4– cells were flow- sorted 
after treating naïve TG peritoneal myeloid cells with IFNα for 
24 hours. The amount of MiR130b found in the media of the 
SLFN4+ cells was 4.5- fold higher than the amount present in 
the SLFN4– media (figure 2C). Since Slfn4 is a Gli1- dependent 
gene inducibly regulated by IFNα,1 6 we showed that MiR130b 
expression in SLFN4+ cells was also Gli1- dependent by 
treating the peritoneal myeloid cells isolated from Gli1–/–:Slfn4- 
tdTomato+ vs Slfn4- tdTomato+ mice with IFNα (online supple-
mentary figure S3A).
MIR130b was also highly expressed in human gastric cancer 
cells and surrounding immune cells compared with normal tissue 
(figure 2D). Since SLFN12L is the closest human homologue of 
mouse Slfn4 and also marks human MDSCs,6 we colocalised 
SLFN12L protein with MIR130b by ISH in the gastric cancer 
tissue (figure 2E). MIR130b and SLFN12L also coexpressed 
in the HL-60 human myeloid line after coculturing with H. 
pylori (online supplementary figure S3B). Knockdown of GLI1 
prevented SLFN12L and MIR130b mRNA expression in the 
presence of H. pylori (online supplementary figure S3B, C). 
Moreover, similar to Slfn4, IFNα strongly induced SLFN12L 
(online supplementary figure S3D, E). HL-60 cells treated 
with H. pylori with or without the GLI1 inhibitor GANT61 or 
GLI1 siRNA blocked both MIR130b and SLFN12L induction, 
indicating that MIR130b expression correlates with Slfn4 and 
SLFN12L myeloid expression in a GLI1- dependent manner.
We used qPCR to determine the levels of MIR130b in archived 
sera collected from 115 Vietnamese patients with gastritis, 
atrophy or atrophy plus intestinal metaplasia (online supple-
mentary table S1 and figure 2F) and found significantly elevated 
serum levels of MIR130b only in patients with atrophy and 
metaplasia. Furthermore, analysis of a cohort of Chinese gastric 
cancer patients similarly demonstrated elevated serum levels 
of MIR130b (online supplementary table S2 and figure 2G). 
Therefore, as observed in Helicobacter- induced SPEM in mice, 
elevated MIR130b levels were observed in the serum of patients 
with intestinal metaplasia and gastric cancer.
MIr130b is essential for SlFn+-MDSC activity
Slfn4 is highly induced in peritoneal myeloid cells treated with 
IFNα and acquire the ability to suppress T cell proliferation.6 
Therefore, to examine the functional effect of the microRNA 
on SLFN4+ cells, we compared the effect of knocking down 
endogenous MiR130b during IFNα induction of Slfn4 to 
MiR130b overexpression with the mimic. Knocking down Slfn4 
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Figure 1 MiRNA analysis of SLFN4+ cells with miRNA profiling. WT chimeric mice reconstituted with Slfn4- tdT bone marrow were treated with 
Tx 2 weeks prior to euthanisation. SLFN4+ versus SLFN4– cells sorted from stomach (ST4+/–), spleen (SP4+/–) and bone marrow (BM4+/–) were 
profiled by the miRNA NanoString nCounter Array. (A) Cluster analysis of differentially expressed miRNAs. (B) A Venn diagram of the upregulated and 
downregulated miRNAs in ST4+ versus ST4– and ST4+ versus SP4+ versus BM4+ after miRNA profiling. Each sample was pooled from five mice. N=2 
separate flow sorts. One- way ANOVA test. Cut- off value: p<0.05. ANOVA, analysis of variance.
with siRNA abolished the induction of MiR130b; however, 
knocking down MiR130b did not inhibit Slfn4 induction by 
IFNα, indicating that Slfn4 was required for MiR130b induction 
(figure 3A). IFNα, but not treatment with the MiR130b mimic 
induced Arg1 and Nos2 expression. However, either Slfn4 or 
MiR130b antisense abolished the IFNα induction of these two 
mRNAs, demonstrating a requirement for MiR130b and Slfn4 in 
the expression of enzymes characteristic of MDSCs function. To 
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Figure 2 MIR130b correlates with mouse SLFN4 and human SLFN12L expression. Thioglycollate- elicited peritoneal cells collected from Slfn4- tdT 
mice were treated with IFNα (800 U/mL) or were NT. (A) Time course of mRNA expression for Slfn4 and MiR130b were analysed by qPCR and B) by 
FISH for MiR130b (green) colocalising with immunofluorescent staining for Slfn4- tdT (red). N=5 expts. Scale bar=50 µm. One- way ANOVA followed 
by Tukey’s multiple comparisons test on log- transformed values. P values are relative to UI or time 0. (C) Flow- sorted SLFN4+ versus SLFN4– cells after 
IFNα treatment were cultured for 24 hours; then, conditioned media was collected. MiR130b secreted into the media was determined by qPCR. Mann- 
Whitney U test was performed. (D) Combined MIR130b ISH and IHC detection in normal tissue and gastric cancer tissue collected from patients with 
gastric cancer. Dotted black lines mark cancer cells and dotted red lines mark immune cells positive for MIR130b expression. Representative staining 
from three out of five GC samples. (E) FISH with MIR130b primers (green) followed by immunofluorescent staining for SLFN12L (red), merged view 
and H&E stained tissue. Scale bar=100 µm. Serum MIR130b levels were determined by qPCR in (F) patients with gastritis, n=27–31 per group for four 
groups of patients: Gastritis without active Helicobacter pylori infection (IgG+,CLO-); Gastritis with active H. pylori infection (CLO+); with atrophy and 
with intestinal metaplasia. P values are relative to gastritis without active H. pylori infection group and in (G) patients with gastric cancer, n=21–63 
per group. Significance was determined using Kruskal- Wallis ANOVA with Dunn’s test of multiple comparisons. *P<0.05, **P<0.01, ***P<0.001. 
Horizontal lines represent the median and IQR. ANOVA, analysis of variance; NT, not- treated.
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Figure 3 MiR130b is essential for SLFN4+- MDSC activity. (A) TG- elicited PCs collected from WT mice were transfected with MiR130b mimic, 
MiR130b antisense (a- 130b), Slfn4 siRNA or scrambled control (Scr) and then treated with IFNα (800 U/mL) or PBS for 24 hours. Differential gene 
expression was evaluated by qPCR. N=5 expts. (B) Protocol to collect SLFN4+ cells for coculture with T cells. TG- elicited PCs from Slfn4- tdT mice were 
treated with IFNα for 24 hours and then flow- sorted for SLFN4+ and SLFN4– cells. Sorted cells were then transfected with MiR130b mimic, antisense 
or Scr. These sorted cells and NT peritoneal cells were cocultured with activated T cells for 72 hours. (C) CFSE- based T cell suppression assay was 
quantified by flow cytometry. The top four representative histograms show proliferation of control groups: NO CFSE, without anti- CD3/28 microbeads 
activation, with CD3/28 only and cocultured with Tregs (CD4+CD25+). The median percentage of proliferating T cells is shown in the representative 
histograms and plotted for n=4 expts in the (D) bar graph. One- way ANOVA followed by Tukey’s multiple comparisons test on log- transformed values. 
The mice infected with Helicobacter felis for 4 months were treated with MIR130b antisense or scrambled control using Invivofectamine. Three weeks 
postinjection, (E) CD45+CD8+ cytotoxic T cells in the stomach were detected by flow cytometry and (F) metaplastic change was shown by H&E, CD44 
variant 9 (red), GSII (green) and clusterin (green) staining. N=3 expts. *P values are relative to IFNα-treated group. #P values are relative to CON or 
scrambled. * or #p<0.05, ** or ##p<0.01, *** or ###p<0.001, ####p<0.0001. NS, not significant. The median and IQR is shown. ANOVA, analysis of 
variance; NT, non- treated; PCs, peritoneal myeloid cells; TG, thioglycollate; UI, uninfected.
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determine directly whether SLFN4+- MDSCs require MiR130b 
for T cell suppressor function, we flow- sorted SLFN4+ and 
SLFN4– cells from TG peritoneal myeloid cells treated with 
IFNα and cocultured them with T cells after transfecting with 
MiR130b mimic, antisense or scrambled oligos (figure 3B). As 
expected, Tregs (splenic CD4+CD25+) inhibited T cell prolifer-
ation (figure 3C,D). Flow- sorted SLFN4+ cells inhibited T cell 
proliferation by 60% (from 57.4% to 22%). However, no signif-
icant T cell suppression was observed when SLFN4– cells or 
untreated TG peritoneal myeloid cells were cocultured with acti-
vated T cells (figure 3, NT). Transfecting SLFN4– cells with the 
MiR130b mimic was not sufficient to impart T cell suppressor 
function to these cells. However, SLFN4+ cells transfected with 
the MiR130b antisense oligo exhibited only minimal T cell 
suppression. Therefore, MiR130b was required but not suffi-
cient for the SLFN4+ cells to exhibit the MDSC T cell suppressor 
phenotype. To further test the effect of MiR130b, we knocked 
down MiR130b in vivo by IP injecting mice infected with Heli-
cobacter for 4 months with antisense MiR130b using Invivo-
fectamine reagent. Knockdown of MiR130b in the stomach was 
validated by qPCR 3 weeks after transfection (online supplemen-
tary figure S4). Suppression of MiR130b was sufficient to restore 
CD8+ cytotoxic T cell infiltration of the stomach (figure 3E), 
demonstrating impaired MDSC function. Less SPEM developed 
after knocking down MiR130b in vivo as shown by reduced 
Clusterin and coexpression of CD44 with GSII at the base of 
gastric glands (figure 3F) as well as less Tff2, Clusterin (Clu) 
and CD44v9 mRNA without significant recovery of parietal and 
chief cell markers H/K- ATPase α subunit (Atp4a), Gif, respec-
tively (online supplementary figure S5).
MIr130b promotes gastric epithelial cell proliferation and 
xenograft tumour formation
Since MIR130b was detected in the media of cultured SLFN+- 
MDSCs, we tested whether MIR130b exerts a proliferative 
effect on gastric epithelial cells in addition to regulating MDSC 
activity. Gastric cell proliferation was measured after transfecting 
AGS cells, a human gastric cancer cell line, and non- transformed 
mouse or human gastric organoids with MIR130b mimic or 
antisense. The MIR130b mimic induced AGS cell proliferation, 
while addition of MIR130b antisense decreased proliferation 
(online supplementary figure S6). Proliferating cells within 
gastric organoids from normal mice or human subjects were 
labelled with EdU and quantified by immunofluorescent staining 
and flow cytometry. MIR130b mimic doubled the number of 
proliferating cells, while the antisense did not significantly 
affect proliferation (figure 4A, online supplementary figure 
S7). Mouse gastric organoids were then cocultured with flow- 
sorted SLFN4+ or SLFN4– cells prepared after treating the TG 
peritoneal myeloid cells from the Slfn4- tdTomato mice with 
IFNα cultured in transwells. The 0.4 µm pore size of the insert 
membrane permitted diffusion of soluble factors from myeloid 
cells in the upper chamber to the lower chamber containing 
mouse organoids while preventing the transfer of any cells. After 
48 hours, mouse gastric organoids cocultured with IFNα-in-
duced SLFN4+ cells exhibited a greater number of proliferating 
cells than organoids cultured with SLFN4– cells (figure 4B). 
Knocking down MIR130b significantly reduced this induction. 
Thus, SLFN4+- MDSCs secreted MiR130b, which was capable of 
promoting gastric epithelial proliferation.
Next, we examined the effect of MIR130b using a xenograft 
tumour model generated using patient- derived organoids from 
three human gastric cancers (diffuse, intestinal, signet ring). 
Organoids were pretreated with either scrambled, MiR130b 
mimic or antisense oligos before injecting into the right flank 
of immune- deficient NSG mice. Xenograft tumour volumes 
from the different organoid lines are shown in figure 4D–F. 
Tumour growth was observed in the scrambled group. 
However, the mimic- treated group doubled their tumour size 
while few antisense- treated organoids developed into tumours 
(figure 4C,D). To rule out the possibility that organoids in 
the antisense group were not viable, a cell viability assay was 
performed on organoids transfected with mimic, antisense or 
scrambled sequences prior to xenograft transplantation. All 
groups exhibited 60%–70% viability after transfection (online 
supplementary figure S8). Immunofluorescence using an anti-
body specific for human histone H3 confirmed engraftment of 
human- derived cells (online supplementary figure S9). Although 
differences in the MIR130b serum levels were not statistically 
significantly, the microRNA levels in xenograft tumours were 
significantly higher in the mimic group and knocked down in the 
antisense group (figure 4G). Collectively, MIR130b exhibited a 
pro- proliferative effect on gastric epithelial cells while reducing 
MIR130b tissue levels exerted a remarkable antitumour effect.
MIr130b targets cylindromatosis (Cyld) and induces nFκb 
activity
TargetScan V.7.0 was used to predict direct downstream gene 
targets that MIR130b potentially regulates. A heatmap was 
generated showing MIR130b gene targets from the public data-
base that overlapped with transcripts differentially expressed 
in the RNA- seq data (figure 5A). The tumour suppressor genes 
Runx3, Trp53inp1, Cebpε, Pten and Cyld are previously reported 
MIR130b targets in various tissues11–17 and were expressed in the 
ST4+ cells at much lower levels than the BM4+ and SP4+ cells. 
Transfecting SLFN4+ peritoneal myeloid cells with the MIR130b 
mimic or antisense oligos showed that the mimic significantly 
suppressed Cyld and Trp53inp1, suggesting that they might be 
the relevant direct targets of MIR130b in these myeloid cells 
(online supplementary figure S10). Indeed, the cylindromatosis 
gene (CYLD) encodes a deubiquitinating enzyme that inhibits 
ubiquitination of Iκb and retains the NFκb heterodimer p65/
p50 in the cytoplasm (figure 5B). Cyld was recently shown to 
be a bona fide target of MIR130b and that the NFκb subunit 
p65 was a potential regulator of the MIR130b locus.13 18 There-
fore, we determined whether there is a feedback loop between 
NFκb activation and MIR130b expression, by using the human 
myeloid HL-60 cell line. The three predicted NFκb binding sites 
in the MIR130b promoter region are shown13 (figure 5B). To 
determine whether NFκb bound to these promoter sites, HL-60 
cells were transfected with scrambled or MIR130b mimic prior 
to performing chromatin immunoprecipitation (ChIP). The 
Iκb promoter was used as a positive control for NFκb binding 
while GAPDH was used as a negative control. NFκb physically 
bound to the MIR130b promoter, and the binding activity was 
enhanced by overexpressing MIR130b (figure 5C). Interest-
ingly, the NOS2 promoter is also a NFκb target.19 Accordingly, 
MIR130b overexpression also induced binding of NFκb to both 
the Nos2 and Iκb promoters, suggesting that MIR130b increases 
the DNA binding activity of NFκb (figure 5C). The MIR130b 
mimic also induced NFκb p65 expression, while knocking down 
endogenous MIR130b reduced basal levels of p65 and blocked 
induction by TNFα (figure 5D). These results demonstrated 
that NFκb induces MIR130b expression by directly binding to 
its promoter, and that MIR130b subsequently induces NFκb 
expression and activity.
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Figure 4 MiR130b promotes gastric epithelial cell proliferation and xenograft tumour formation. Gastric organoids from wildtype mice were (A) 
transfected with MiR130b mimic, MiR130b antisense (a- 130b) or scrambled control (Scr) or (B) cocultured with flow- sorted SLFN4– or SLFN4+ cells 
transfected with a- 130b or Scr in the transwell system for 48 hours. Organoids were then stained with EdU antibody. EdU+ cells were visualised by 
(A) confocal or (B) quantified by flow cytometry. Quantified data were plotted in bar graphs. N=4 expts. Xenograft assays were performed by injecting 
subcutaneously into the right flank of the NSG mice 3 human gastric cancer patient derived organoid lines (TGO1=Diffuse type; TGO2=intestinal type; 
TGO4=poorly differentiated with signet ring cells) transfected with MiR130b mimic, antisense or Scr. (C) Right flank of mice at the end of the 
xenograft assay. Tumour height (h), length (l) and width (w) from three different xenograft (D–F) were measured every 4 days using a calliper. Tumour 
volume was plotted over a 36- day time course post- transplant. *Significance compared with Scr group. (G) MiR130b expression determined by RT- 
qPCR in NSG mouse serum and tumour tissue. One- way ANOVA followed by Tukey’s multiple comparisons test on log- transformed values. N=10 mice 
across three expts. *P<0.05, **P<0.01. Horizontal lines represent the median and IQR. ANOVA, analysis of variance; TGO, tumour gastric organoid.
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Figure 5 MIR130b targets cylindromatosis (CYLD) and induces NFkb activity. (A) Microarray heat map of MIR130b candidate targets predicted by 
TargetScan or reported previously. Samples were pooled from five mice per expt. N=2 expts. (B) Hypothetical model illustrating the NFκB/MIR130b/
CYLD axis and schematic of a typical MIR130b promoter. The predicted NFκB binding sites were located at −229 to −239, –474 to −484 and −1467 
to −1477 upstream of the transcription start site. NFκB upregulates the transcription of MIR130b, which targets and decreases CYLD expression and 
disrupts the negative feedback of CYLD on NFκB activation. This axis constitutively activates NFκB. (C) Chromatin immunoprecipitation (ChIP) assay 
using HL-60 cells showed that the NFκB physically bound to the promoters13 as indicated (online supplementary methods). Lane 1, input chromatin 
prior to immunoprecipitation. Lane 2, immunoprecipitation with a non- specific antibody (IgG). Lanes 3 and 4, immunoprecipitation with NFκB P65 
antibody after the cells were transfected with lane three scrambled control (Scr) or lane 4 MIR130b mimic. Lane 5, immunoprecipitation with RNA 
polymerase II (RNAP II) antibody as a positive control. (D) HL-60 cells were treated with TNFα, MIR130b mimic, antisense (a- 130b) or TNFα plus 
MIR130b antisense (TNFα/a- 130b). NFkb p65 expression was determined by Western blot. GAPDH as a loading control. N=5 expts. (E) Western blot of 
CYLD and NFkB- p65 expression in cytoplasmic and nuclear fractions of xenograft tumours from scrambled control (Scr), mimic and a- 130b groups. (F) 
Bar graphs show quantitation using ImageJ. α-tubulin and histone-3 served as cytoplasmic and nucleic loading control, respectively. N=3 expts. One- 
way ANOVA followed by Tukey’s multiple comparisons test on log- transformed values. *P<0.05, the median±IQR. ANOVA, analysis of variance.
Immunohistochemistry for p65 in the xenografts (online 
supplementary figure S11) and western blots of the cytoplasmic 
and nuclear extracts showed that NFκb translocates to the 
nucleus in the mimic- treated group (figure 5E,F). We observed 
higher expression of NFκb in both the cytoplasm and nucleus, 
which inversely correlated with CYLD expression, suggesting 
that increased NFκb activity contributed to accelerated tumour 
growth observed with the MIR130b mimic.
DISCuSSIOn
SLFN4 is a known myeloid differentiation and T cell quiescence 
factor.1 4 6 We previously reported that Slfn4 marks a subset of 
CD11b+Gr-1+ MDSCs that coincide with Helicobacter- induced 
SPEM.6 Here, we demonstrate that SLFN4+- MDSCs modulate 
their suppressor function by producing MiR130b.
The MIR130 family has been linked to several types of cancers, 
including glioma,18 20 hepatocellular carcinoma,11 21 colorectal,17 
pancreatic,22 renal cell,23 endometrial,24 bladder,13 breast15 as 
well as gastric cancer.25 26 MIR130b exerts its proneoplastic func-
tion by modulating multiple signalling pathways and suppressing 
expression of tumour suppressors such as TP53INP1,11 
RUNX3,12 CYLD13 14 or PTEN,15 which promote self- renewal 
of tumour- initiating cells, proliferation, invasion and migra-
tion of various cancer cells. We show here that IFNα-polarised 
SLFN4+- MDSCs activate the NFκb pathway, which directly 
induces MIR130b expression (figure 6). Subsequently, MIR130b 
can sustain persistent activation of NFκb, as previously reported 
for bladder cancer.13 Combining our RNA- Seq with in vitro 
cell line analysis, we surmised that Cylindromatosis (CYLD) 
is one of the MIR130b gene targets that likely contributes to 
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Figure 6 Schematic of SLFN4+-MDSCs polarised in the stomach during Helicobacter infection. Acute SHH release by parietal cells into the 
circulation is sensed by BM- derived SLFN4+ myeloid cells (green), which are home to the infected stomach. Eventually, the SLFN4+ myeloid cells 
become activated and polarised to MDSCs (red) and accumulate in response to tissue IFNα produced during chronic Helicobacter infection. There 
is a feedback loop between NFκb activation and MIR130b expression in SLFN+- MDSCs (enlarged red cell). MiR130b produced by SLFN+- MDSCs (1) 
regulate T cell suppressor function, (2) affect epithelial cell proliferation, (3) promote metaplastic changes. MDSCs, myeloid- derived suppressor cells; 
SHH, Sonic hedgehog.
SLFN4+- MDSC function. CYLD is a deubiquitinase that can 
directly interact with an essential modulator of NFκb and the 
TNFR- associated factor TRAF2 to negatively regulate NFκb 
activity. It is noteworthy that there are NFκb response elements 
within the MIR130b promoter.13 Moreover, NFκb modulates 
multiple signalling pathways, perhaps explaining how MIR130b 
coordinately regulates several genes.
A by- product of the elevated tissue levels of MIR130b 
includes detectable levels in the circulation. While other sources 
of MIR130b likely exist, we observed in both mouse and human 
blood that elevated MIR130b levels correlate with preneoplastic 
events in the stomach. Moreover, MIR130b colocalised with 
human SLFN12L in immune cells adjacent gastric cancer cells, 
which coincided with its presence in the blood of these patients. 
This clinical evidence supports a close association between 
circulating MIR130b initially with gastric metaplasia that also 
remains elevated in gastric cancer. Since microRNAs remain 
stable in the circulation, they can function as biomarkers of 
disease.8 Indeed, lymphocytes secrete microvesicles laden with 
MIR130b that regulate recipient cells.27 Whether blood levels 
of circulating MIR130b prove to be a relevant biomarker awaits 
prospective validation.
Knockdown of MiR130b abolished the SLFN4+- MDSC T 
cell suppressive effect, suggesting that MiR130b is required for 
acquisition of MDSC function. Specifically, MiR130b suppres-
sion abolished Arg1 and Nos2 induction, required for MDSC 
activation. In addition to their immunosuppressive function, 
MDSCs also affect remodelling of the tumour microenvironment 
by producing a variety of cytokines and other molecules that 
can promote epithelial proliferation.28–30 Functional microRNAs 
can be exported and delivered to recipient cells typically by 
exosomes to regulate target cells. Treating primary myeloid cells, 
a gastric cell line and gastric organoids with MIR130b mimic 
showed that MIR130b promotes epithelial cell proliferation. 
A xenograft model of human- derived gastric cancer organoids 
further confirmed an essential role of MIR130b in promoting 
tumour formation. Since MIR130b directly stimulates epithelial 
cell proliferation, it might also contribute to metaplasia to cancer 
progression, in addition to creating a permissive immune micro-
environment through T cell suppression.
In summary, we show here that MIR130b has potential as 
a diagnostic and therapeutic biomarker for metaplasia in the 
stomach that progresses to gastric cancer. Indeed, secreted 
microRNAs are recognised as mediators of intercellular commu-
nication and stable circulating biomarkers of disease.8 More-
over, some clinical trials have now emerged using miRNA- based 
therapeutics.31
MATerIAlS AnD MeTHODS
Transgenic mice
Gli1nLacZ/nLacZ (referred to Gli1–/–), SLFN4- CreERT2/Rosa26- 
tdTomato (SLFN4- tdT) and SLFN4- CreERT2/Rosa26- tdTomato/
Gli1–/– (SLFN4- tdT/Gli1–/–) transgenic mouse lines have been 
previously described.1 6 All mice were cohoused under the same 
specific pathogen- free conditions and were maintained on a 
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genetic background. The University of Michigan and the Univer-
sity of Arizona Institutional Animal Care and Use Committee 
approved all mouse protocols used in this study.
Patient samples
Expression of serum MIR130b was determined by qPCR from 
two cohorts of deidentified human patients: 115 subjects with 
gastritis from the Institute of Biotechnology in Vietnam (online 
supplementary table S1) (IRBMED; ID: HUM00108090). 
Detection of H. pylori infection was performed using H. pylori 
IgG ELISA and campylobacter- like organism (CLO) test (for 
active infection). The pathological diagnosis was determined by 
a GI pathologist blinded to the clinical diagnosis. Eighty- four 
samples were from Xiangya Hospital (China) (IRBMED; ID: 
HUM00113773), containing 21 healthy controls and 63 patients 
with gastric cancer (online supplementary table S2). Colocalisa-
tion of MIR130b determined by FISH and SLFN12L determined 
by immunofluorescence was performed in gastric cancer speci-
mens and normal tissue collected from five deidentified patients 
who underwent surgery at Xiangya Hospital in 2016 (IRBMED; 
ID: HUM00113773).
Single cell preparation for transcriptome analysis
Cells isolated from stomach, spleen and bone marrow for 
RNAseq and microRNA array were prepared as described previ-
ously.6 The single cell suspension from different tissues was 
flow- sorted to collect Cd11b+SLFN4+ and Cd11b+SLFN4– cells 
based on tdTomato expression, using an iCyt Synergy Flow 
Sorter (Sony Biotechnology). To obtain sufficient mRNA for 
analysis, cells isolated and sorted from five mice infected with 
H. felis (as described previously6 for 6 months were pooled for 
one experiment. All six groups (ST4+, ST4–, BMS4+, BM4–, 
SP4+, SPS4–) of cells were from two independent experiments. 
Total RNA was extracted in TRIzol LS Reagent (Invitrogen) and 
purified using the miRNeasy Mini kit (Qiagen). The RNA integ-
rity was assessed using the Bioanalyzer 2100 system (Agilent 
Technologies).
Nanostring nCounter miRNA assay for miRNA profiling
MiRNA profiling was performed at the UCLA Center for Systems 
Biomedicine, using the NanoString nCounter Mouse V.1.5 
miRNA Expression Assay Kit (NanoString), in which more than 
600 pairs of probes specific for a set of miRNAs was combined 
with a series of internal controls to form the Mouse miRNA 
Panel Code Set. Details are in the Supplementary Methods.
In situ hybridisation (ISH) detection of mirnA
ISH detection of MiR130b was performed using cells cultured 
on coverslips or paraffin tissue sections. The sections were 
deparaffinized in xylene and rehydrated in serial ethanol solu-
tions and DEPC- treated water, then digested with 20 µg/mL 
proteinase K for 5 min at 37°C. For both cells and tissues, a 
prehybridisation incubation was performed using a 50% forma-
mide Denhardt’s solution for 1 hour at 55°C. The single strand 
DNA probes labelled with 5’ 6- FAM and 3’ DIG were diluted to 
a working concentration of 50 ng/mL with hybridisation buffer 
and incubated for 24 hours at 60°C. Samples were washed with 
50% formamide in 5× sodium citrate saline (pH 7.0) buffer for 
20 min at 40°C. Samples were rinsed with DEPC- treated water 
prior to the diaminobenzidine based immunohistochemistry 
(Abcam, ab4238) or immunofluorescent staining of SLFN4 or 
SLFN12L. Probes were purchased from Integrative DNA Tech-
nologies, sense probe as a negative control.
MiR130b- 3p probe: 5’6- FAM/ ATGC CCTT TCAT CATT 
GCACTG/3’DIG.
MiR130b- 3p control probe: 5’6- FAM/  CAGT GCAA TGAT 
GAAA GGGCAT /3’DIG.
Cell culture and treatment
TG- elicited peritoneal myeloid cells were prepared from the 
Slfn4- tdT mice, as described previously.6 Cells were treated with 
100 nM Tamoxifen (Tx, dissolved in DMSO) for 24 hours to 
induce Cre recombinase activity and tdTomato expression ex 
vivo. The Hsa- MIR130b- 3p miRNA mimic (50 nM, Applied 
Biological Materials, MCH01270) and the mimic negative 
control (MCH00000) were transfected into cells using Lipo-
fectamine LTX with PLUS reagent (Thermo Fisher). The Mmu- 
Mir130b- 3p miRNA antisense ( CAGU GCAA UGAU GAAA 
GGGCAU) (10 nM, MSTUD0173, Sigma Aldrich), Slfn4 siRNA 
or the scrambled controls were transfected using Lipofectamine 
RNAiMAX transfection reagent (Thermo Fisher) for 48 hours. 
To induce Slfn4 expression, the cells were treated with 800 U/
mL recombinant IFNα (R&D, #12 125–1) for 24 hours or at 
different time points.
T cell suppression assay
Carboxyfluorescein diacetate succinimidyl ester based T cell 
suppression assay was performed as described previously.6 Peri-
toneal cells isolated from Slfn4- tdT mice were treated with IFNα 
(800 U/mL) for 24 hours and then flow- sorted for SLFN4+ (tdTo-
mato, red) and SLFN4– cells (figure 3B). SLFN4+ and SLFN4– 
cells were then transfected with MiR130b mimic, antisense or 
scrambled control for 48 hours. Suppression of T cell prolifera-
tion was assayed after the addition of SLFN4+ or SLFN4– cells 
for 3 days at a T cell/SLFN4 cell ratio of 10:1. Cell prolifera-
tion was analysed using an Attune Acoustic Focusing cytometer 
(Applied Biosystem).
In vivo rnAi transfection
MiR130b antisense or scrambled control were combined with a 
lipid- based in vivo RNAi transfection reagent Invivofectamine 
3.0 (Invitrogen) according to the manufacturer’s instruction. 
Three mice infected with H. felis for 4 months were injected 
intraperitoneally once with 1.5 mg/kg of the antisense or scram-
bled oligo complexes. Three weeks after the infection, the mice 
were necropsied and their stomachs were collected for histology. 
A single cell suspension was generated for flow cytometry.
Organoid/cell coculture
Mouse gastric organoids suspended in Matrigel were seeded 
in each well and then overlaid with gastric organoid media as 
described above. Peritoneal myeloid cells treated with IFNα 
as described above were flow- sorted into SLFN4+ or SLFN4– 
groups. Next 105 of either SLFN4+ or SLFN4– cells were plated 
onto the 24 mm polycarbonate membrane insert (0.4 µm pore 
diameter; Corning) with 0.5% FBS in growth media. To initiate 
the coculture, inserts were combined with the wells for an addi-
tional 48 hours.
Xenograft assay
Tumour derived organoid lines were generated using the stomach 
tissue from three patients with gastric cancer following a previ-
ously described protocol.32 TGO1 was from a diffuse type, 
TGO2 from an intestinal type and TGO4 from a poorly differ-
entiated adenocarcinoma with diffuse and signet ring cell types. 
The organoids transfected with MIR130b mimic, antisense or 
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scrambled and cultured for 48 hours were injected subcutane-
ously into the right flank of NOD Scid Gamma mice. Morpho-
metrics (tumour height, length and width) were measured with 
a calliper every 4 days. Tumour volume was calculated using a 
published equation33. The cell viability assay was performed on 
organoids transfected with Mimic/antisense/scrambled prior to 
xenograft transplantation (online supplementary figure S6) by 
flow cytometry using LIVE/DEAD Viability/Cytotoxicity Kit 
(Thermo Fisher, #L3224).
real-time quantitative PCr
Total RNA from cells was extracted in TRIzol (Invitrogen) and 
purified with the RNeasy Minikit (Qiagen). The qPCR was 
performed as described previously,6 using the primer sequences 
described in online supplementary table S3.
For detection of miR130b, total RNA was extracted from 
200 µL serum using the miRNeasy Serum/Plasma Kit (Qiagen). 
Before RNA extraction, Caenorhabditis elegans miRNA cel- 
miR39 miRNA mimic (Cat#219610, Qiagen) was used to 
spike the serum samples as an endogenous control for normal-
isation during extraction. The stem- loop reverse transcription 
and subsequent qPCR was performed using the Hsa- MIR130b 
real- time RT- PCR detection and cel- miR-39–3 p calibration kit 
(#MBS8244866, Mybiosource) according to the manufacturer’s 
instructions. Stem- loop RT primers specific for MIR130b and 
cel-mir39- 3p bind to the 3’ portion of miRNA for transcrip-
tion with reverse transcriptase. The RT product was quantified 
using real- time PCR that includes a specific primer set and SYBR 
Green dye under the following conditions: initial denaturation 
at 95°C for 3 m followed by 40 cycles of denaturation at 95°C 
for 12 s; annealing and extension at 62°C for 40 s. Fluorescence 
was detected using the CFX96 real- time PCR detection system 
(Bio- RAD).
Statistics
For qPCR and proliferation experiments, statistical analysis for 
significance was performed on the log- transformed values using 
1- way analysis of variance with Tukey’s posthoc test for multiple 
comparisons (GraphPad Prism). All data were expressed as the 
median with the IQR. P<0.05 were considered statistically 
significant. The number of samples per group and replicate 
experiments are indicated in the figure legends.
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